Dynavax Technologies Corporation (DVAX) News
Filter DVAX News Items
DVAX News Results
|Loading, please wait...|
DVAX News Highlights
- DVAX's 30 day story count now stands at 20.
- Over the past 19 days, the trend for DVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about DVAX are BEAM, BEAT and DRUG.
Latest DVAX News From Around the Web
Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.
Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET.
Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.
SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.
AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.
AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.
Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.